NOVALIQ’S NOVATEARS® TREATMENT FOR EVAPORATIVE DRY EYE DISEASE IS NOW AVAILABLE ACROSS AUSTRALIA AND NEW ZEALAND

Heidelberg, Germany – June 28, 2018 – Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced that NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia. Dry eye is…